Discussion
The U.S. Food and Drug Administration (FDA) has given Pheno Therapeutics the green light to begin clinical testing of PTD802, the company’s oral lead treatment candidate for boosting myelin repair in people with multiple sclerosis (MS) and other neurological diseases. The experimental remyelination therapy aims to potentially…